Company Product Description Indication Status
Arch Biopartners Inc., of Toronto Metablok LSALT peptide COVID-19 Submitted CTA to Health Canada for a phase II study to prevent lung and kidney inflammation in COVID-19 patients
Biosig Technologies Inc., of Westport, Conn., and subsidiary Viralclear Pharmaceuticals Inc. Merimepodib Broad-spectrum antiviral COVID-19 Viralclear submitted IND to FDA for phase II trial
Innovent Biologics Inc., of Suzhou, China, and Eli Lilly and Co., of Indianapolis Tyvyt (sintilimab) Anti-PD-1 monoclonal antibody Nonsquamous non-small-cell lung cancer China’s NMPA accepted the sNDA seeking approval for use in combination with Alimta (pemetrexed, Lilly) and platinum chemo as first-line therapy
Janssen Pharmaceutical Cos., of Horsham, Pa. Simponi Aria (golimumab) Anti-TNF-alpha biologic for intravenous injection Polyarticular juvenile idiopathic arthritis Submitted supplemental BLA to the FDA seeking approval for use in patients, 2 and older, in combination with methotrexate
Janssen Pharmaceutical Cos., of Horsham, Pa. Simponi Aria (golimumab) Anti-TNF-alpha biologic for intravenous injection Juvenile psoriatic arthritis Submitted supplemental BLA to the FDA seeking approval for use in patients, 2 and older, in combination with methotrexate
Oryzon Genomics SA, of Madrid Vafidemstat Oral, CNS optimized LSD1 inhibitor COVID-19 Received approval from Spanish drug agency (AEMPS) to conduct phase II study in seriously ill patients
Sanofi SA, of Paris Menquadfi Meningococcal (groups A, C, Y, W) conjugate vaccine Meningococcal disease  FDA approved BLA for the prevention of invasive disease in persons 2 and older

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments